Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, SCZ

The SeniorCare Investor to Host Webinar, Assisted Living: Acquiring and Selling in Today's Turbulent Market


NORWALK, Conn., Oct. 10, 2019 /PRNewswire-PRWeb/ -- We are now nine years past the Great Recession, when it was discovered that assisted living was recession-resistant because when you need the care, there are not too many options. The assisted living market has grown significantly since the end of the recession in 2009, and values have been hovering near a market peak, despite all the occupancy, development and labor headwinds. For the right property, buyers have been known to acquire based on a 5% and even 4% cap rate, assuming the headwinds will dissipate or not impact a trophy property. But with talk of a much-delayed potential recession hitting the economy in the next year or two, will the assisted living acquisition market really continue on unabated? The majority of the properties will be over 20 years old by 2020, and some are showing their age. Does that mean it is time to sell and at what price?

Our moderators, Ben Swett, Editor of The SeniorCare Investor and Senior Care Acquisition Reports, and Steve Monroe, Managing Editor, will pose relevant topics such as: What are investors really thinking about traditional assisted living values, and will age have much of an impact; Who is selling at a time when the market may have already peaked; Who is buying, and are they expecting a resurgence in activity and values after the market absorbs all the recent development; Will lenders continue to supply the capital needed for an active acquisition market, and to support even higher values; When will cap rates start to decline, if at all.

Assisted living has seen the most development activity of all of seniors housing and care for the past several years, but will it be enough for the aging baby boomers, and will these boomers want something that was built 20 years ago? This is what buyers, investors, and developers will have to think about as they invest in this sector over the next several years, and at what price.

Plus, you will have an opportunity to ask the experts your questions during the live Q&A. Our panel of experts will include Jay Wagner, Executive Managing Director ? National Seniors Housing Capital Markets, Cushman & Wakefield, Matthew Whitlock, Managing Director & Chief Investment Officer ? Senior Housing, Berkshire Residential Investments, and Chris Hollister, Co-Founder & Vice-Chairman, Pegasus Senior Living.

If interested in this topic, then don't miss the live webinar on October 17, 2019, at 1:00 pm ET. If unable to attend the live webinar, a recording with be available the following day.

Please visit https://products.levinassociates.com/downloads/1910web/ or call 203-846-6800 for more information about this interactive webinar.

SOURCE Irving Levin Associates


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: